...
首页> 外文期刊>International journal of hematology >Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation
【24h】

Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation

机译:Busulfan清关并未预测经过造血干细胞移植患者的肝静脉闭塞病的发展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Hepatic veno-occlusive disease (VOD) is a life-threatening complication following hematopoietic stem cell transplant (HSCT). Busulfan has a narrow therapeutic index and its concentration was found to correlate with VOD. Our primary objective was to assess the association between busulfan clearance and VOD in HSCT patients. In this retrospective analysis, we included patients who received their HSCT between 2003 and 2014 and followed at Sultan Qaboos University Hospital. All patients who received dose-targeted busulfan-containing conditioning were included. Target steady-state concentration (Css) was 800-900 ng/ml. VOD was assessed using modified Seattle criteria. The impact of busulfan clearance on VOD was analyzed using univariable logistic regression model. Seventy-three patients were included with a mean age of 15 years. Of those, 47% were transplanted for hematological malignancies and 53% for inherited hemoglobinopathies. Target Css was achieved in 85% of patients. The rate of VOD was 17%. There was no significant impact of busulfan clearance (p = 0.919) or area-under-the-concentration-time-curve (p = 0.275) on VOD. Targeting busulfan Css into narrow therapeutic range may have accounted for the findings. The risk of VOD might be related to other factors such as the genetic background, and more studies are required to investigate these factors.
机译:肝静脉闭塞性疾病(VOD)是造血干细胞移植(HSCT)后的危及生命并发症。 Busulfan具有狭窄的治疗指数,并发现其浓度与VOD相关。我们的主要目标是评估HSCT患者Busulfan间隙与VOD之间的关联。在这种回顾性分析中,我们包括在2003年至2014年之间获得其HSCT的患者,并在苏丹Qaboos大学医院接下来。所有接受含剂量靶向血丝的调理的所有患者都包含在内。靶稳态浓度(CSS)为800-900ng / ml。使用改进的西雅图标准评估VOD。利用单变逻辑回归模型分析了Busulfan清除对VOD的影响。七十三名患者包含15年的平均年龄。其中,47%用于移植血液恶性恶性肿瘤,遗传血管病毒缺乏症53%。在85%的患者中取得了目标CSS。 VOD率为17%。 Busulfan间隙(P = 0.919)或浓度下的时间曲线(P = 0.275)对VOD没有显着影响。将Busulfan CSS定位为狭窄的治疗范围可能会占调查结果。 VOD的风险可能与诸如遗传背景等其他因素有关,并且需要更多的研究来研究这些因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号